A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic ...

The Phase 2 study is a multi-center, randomized, partially double-blind, placebo- and active-controlled trial designed to evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 in patients ...

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration ...

Pulmonary Fibrosis Xray Investigators developed a timeline reflecting the diagnosis and treatment of idiopathic pulmonary fibrosis in the US. The average time to diagnosis of IPF was 2.7 years after a ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive, fatal disease of unknown cause. Although there is no known cure, there have been indications that gastroesophageal reflux disease (GERD) ...

The 2011 ATS/ERS/JRS/ALAT guidelines list a number of recommendations for the diagnosis and clinical management of patients with IPF The level of understanding and adherence to the guidelines among ...

Telomere length and polygenic risk scores (PRS) are linked to idiopathic pulmonary fibrosis (IPF) risk, especially in ...

Please provide your email address to receive an email when new articles are posted on . An online survey was created to capture the burden of IPF. Patients frequently reported shortness of breath. IPF ...

Idiopathic pulmonary fibrosis represents a high need specialty market, with global IPF drug sales of roughly USD 3 billion ...

This transcript has been edited for clarity. Fernando J. Martinez, MD: Hi. My name is Fernando Martinez. I'm the chief of pulmonary and critical care medicine at Weill Cornell Medicine. I'm with one ...